Study S001132

Exenatide and Postprandial Endothelial Dysfunction: Effects and Mechanisms

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01181986
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 76
Start: 2010-08
Primary completion: 2012-12
Lead sponsor: Carl T. Hayden VA Medical Center
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Exenatide SC; DRUG:Exenatide IV; DRUG:Placebo SC; DRUG:Exendin-9; DRUG:Placebo IV
Results posted: TRUE

Registered primary outcomes

Reactive Hyperemia Index (RHI) [0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 & 3 (Sub-study 2)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.